Physician profile
Roy F Chemaly
NPI 1609976521
$686,170.21
in general payments reported to CMS, 2019-2025
24 companies · $133K in 2025
The $133K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153K · 2020: $30K · 2021: $57K · 2022: $113K · 2023: $140K · 2024: $60K · 2025: $133K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $116K · Consulting Fee: $114K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Honoraria: $3,750 · Food and Beverage: $1,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $116,190.86 |
| Consulting Fee | $114,019.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,470.00 |
| Honoraria | $3,750.00 |
| Food and Beverage | $1,480.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $399,777.82 | 2019-2025 | Prevymis, Recarbrio, Zerbaxa |
| Takeda Pharmaceuticals U.S.A., INC. | $87,070.37 | 2020-2024 | Livtencity |
| Oxford Immunotec USA INC | $32,495.88 | 2019-2023 | T-Spot.Tb8 |
| Biotest Ag | $22,822.54 | 2023-2025 | |
| Modernatx, INC. | $20,488.00 | 2022-2023 | Moderna Covid-19 Vaccine |
| Adma Biomanufacturing LLC | $20,000.00 | 2019-2020 | |
| F. Hoffmann-La Roche Ag | $18,096.69 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14,610.27 | 2019 | |
| Shionogi INC | $14,141.64 | 2020-2025 | Fetroja, S-217622 |
| Partner Therapeutics, INC. | $10,073.00 | 2020 | |
| Invivyd INC | $8,797.98 | 2024-2025 | Pemgarda |
| Gilead Sciences, INC. | $7,488.27 | 2022-2024 | Veklury |
| Pfizer INC. | $6,000.00 | 2024-2025 | |
| Pierre Fabre Pharmaceuticals, INC. | $4,726.20 | 2025 | |
| Janssen Global Services, LLC | $4,320.00 | 2019-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,464.59 | 2023-2024 | |
| Astellas Pharma US INC | $3,081.20 | 2019-2023 | Cresemba |
| Astrazeneca Pharmaceuticals Lp | $3,000.00 | 2024 | |
| Genmark Diagnostics, INC. | $2,815.76 | 2022 | |
| Qiagen, LLC | $1,500.00 | 2021 | |
| Life Technologies Corporation | $1,400.00 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Chemaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.